Democrats vow to tackle drug prices after midterm victory
The cost: benefit ratio of the rising prices of new oncology treatments and how the pharmaceutical industry and regulators can adequately address them.
A new report from the Social Market Foundation think tank argues that the UK’s National Health Service should switch to paying for medicines based on patient outcomes.
Reports also suggest Trump’s pricing plans may be pro-industry.
Aspen pulled drugs from some countries that rejected price hikes, says EU.